

Navana Pharmaceuticals PLC.

**Financial Statements (Un-audited) for
Second Quarter (Q2), FY 2024-25**

Period: 1st July - 31th December 2024



Navana Pharmaceuticals PLC.
Statement of Financial Position (Un-audited)
As at 31 December 2024


(Amount in BDT)

Particulars	Notes	As at	
		31-Dec-2024	30-Jun-2024
Assets			
Non-Current Assets:			
Property, Plant and Equipment	3.00	4,997,974,408	4,650,941,337
Intangible Asset	3.01	220,000	330,000
Capital Work in Progress	4.00	546,570,161	931,717,844
Right-of-Use Asset	5.00	145,774,909	163,404,672
Investment in Marketable Securities (Fair Value)	6.00	41,058,755	76,920,238
Total Non-Current Assets		5,731,598,233	5,823,314,091
Current Assets:			
Inventories	7.00	1,525,390,572	1,283,188,710
Trade and Other Receivables	8.00	1,080,806,310	1,020,129,897
Advances, Deposits and Prepayments	9.00	2,031,924,349	2,151,093,999
Goods In Transit	10.00	714,849,852	758,207,036
Cash and Cash Equivalents	11.00	282,567,702	267,770,086
Total Current Assets		5,635,538,785	5,480,389,728
Total Assets		11,367,137,018	11,303,703,819
Equity And Liabilities			
Equity:			
Paid-up Share Capital	12.00	1,074,162,170	1,074,162,170
Share Premium		448,170,069	448,170,069
Revaluation Reserve	13.00	1,848,295,335	1,848,295,335
Capital Reserve		605,590,148	605,590,148
Unrealized Gain/ (Loss) Reserve	6.00	(141,676,173)	(123,143,306)
Retained Earnings		902,014,254	708,021,144
Total Equity:		4,736,555,803	4,561,095,560
Liabilities			
Non-Current Liabilities:			
Loan from Directors	14.00	30,000,000	30,000,000
Lease Liabilities	15.01	54,525,758	64,500,095
Long Term Loan	16.01	155,361,175	115,319,266
Bond		80,000,000	80,000,000
Deferred Tax Liability	17.00	143,768,150	158,005,471
Total Non-Current Liabilities		463,655,083	447,824,832
Current Liabilities:			
Short Term Loan	18.00	4,743,439,850	5,008,191,502
Lease Liabilities (Current Maturity)	15.00	41,848,006	43,553,958
Long Term Loan (Current Maturity)	16.00	27,215,894	35,366,036
Trade and Other Payables	19.00	1,347,112,924	1,199,906,960
Unclaim Dividend Payable	20.00	7,309,457	7,764,971
Total Current Liabilities		6,166,926,131	6,294,783,427
Total Liabilities		6,630,581,214	6,742,608,259
Total Equity and Liabilities		11,367,137,018	11,303,703,819
Net Asset Value (NAV) Per Share	30.00	44.10	42.46


Annexed notes are integral part of these financial statements.


 Director Finance & CFO


 Company Secretary


 Acting Managing Director


 Director


 Chairman

Navana Pharmaceuticals PLC.
Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the period from 01 July 2024 to 31 December 2024

(Amount in BDT)


Particulars	Notes	Half Yearly		Second Quarter	
		July-Dec'2024	July-Dec'2023	Oct-Dec'2024	Oct-Dec'2023
Net Sales	21.00	4,363,718,011	3,283,637,823	2,226,315,771	1,652,116,111
Less: Cost of Good Sold	22.00	2,336,947,999	1,753,983,777	1,201,093,153	878,668,658
Gross Profit		2,026,770,012	1,529,654,046	1,025,222,618	773,447,453
Less: Operating Expenses					
Administrative Expenses	23.00	104,071,396	84,529,284	59,328,344	51,550,092
Selling & Marketing Expenses	24.00	890,146,225	721,429,445	454,458,729	373,509,023
Distribution Expenses	25.00	289,078,585	237,839,980	155,297,467	121,603,136
Total Operating Expenses:		1,283,296,206	1,043,798,709	669,084,540	546,662,251
Operating Profit		743,473,806	485,855,337	356,138,078	226,785,202
Less: Finance Expenses	26.00	390,040,025	195,198,225	188,939,808	101,298,283
Add: Other Income/(loss)	27.00	1,454,575	13,192,764	15,057,436	10,053,512
Profit Before WPPF & Tax		354,888,356	303,849,875	182,255,706	135,540,431
Contribution to WPPF		16,899,446	14,469,042	8,678,843	6,454,306
Profit Before tax		337,988,911	289,380,833	173,576,863	129,086,125
Less: Income Tax		96,544,788	65,062,627	65,881,952	24,318,009
Current Tax	28.00	84,303,261	57,540,543	64,534,799	21,948,248
Deferred Tax Expense/(Income)		12,241,527	7,522,084	1,347,152	2,369,760
Profit After Tax		241,444,123	224,318,207	107,694,911	104,768,117
Other Comprehensive Income					
Unrealized Gain/(loss) on Marketable Security		(141,676,173)	(17,140,400)	(130,968,518)	(9,315,188)
Total Comprehensive Income		99,767,950	207,177,807	(23,273,607)	95,452,928
Earnings Per Share (EPS)	29.00	2.25	2.09	1.00	0.98


Annexed notes are integral part of these financial statements.


 Director Finance & CFO


 Company Secretary


 Acting Managing Director


 Director


 Chairman

Navana Pharmaceuticals PLC

Statement of Changes in Equity (Un-audited)

For the period from 01 July 2024 to 31 December 2024


Particulars	Share Capital	Share Premium	Revaluation Reserve	Capital Reserve	Unrealized Gain / (Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2024	1,074,162,170	448,170,069	1,848,295,335	605,590,148	(123,143,306)	708,021,144	4,561,095,560
Profit after Tax	-	-	-	-	-	241,444,123	241,444,123
14% Cash Dividend for YE 30 June 2024	-	-	-	-	-	(47,451,013)	(47,451,013)
Adj. to Unrealized Gain / (Loss) on FVOCI	-	-	-	-	(18,532,867)	-	(18,532,867)
Balance as at 31 December 2024	1,074,162,170	448,170,069	1,848,295,335	605,590,148	(141,676,173)	902,014,254	4,736,555,803


Statement of Changes in Equity (Un-audited)

For the period from 01 July 2023 to 31 December 2023


Particulars	Share Capital	Share Premium	Revaluation Reserve	Capital Reserve	Unrealized Gain / (Loss) Reserve	Retained Earnings	Total
Balance as at 1 July 2023	1,074,162,170	448,170,069	1,848,295,335	605,590,148	(46,800,998)	443,028,348	4,372,445,073
Profit after Tax	-	-	-	-	-	224,318,207	224,318,207
13% Cash Dividend for YE 30 June 2023	-	-	-	-	-	(139,641,082)	(139,641,082)
Adj. to Unrealized Gain / (Loss) on FVOCI	-	-	-	-	(17,140,400)	-	(17,140,400)
Balance as at 31 December 2023	1,074,162,170	448,170,069	1,848,295,335	605,590,148	(63,941,398)	527,705,473	4,439,981,797

Annexed notes are integral part of these financial statements.


Director Finance & CFO


Company Secretary


Acting Managing Director



Director



Chairman


Navana Pharmaceuticals PLC.
Statement of Cash Flows (Un-audited)
For the period from 01 July 2024 to 31 December 2024


Particulars	Notes	July-Dec'2024	July-Dec'2023
Cash Flows from Operating Activities:		339,265,300	93,133,612
Cash Receipts from Customers		4,313,087,401	2,918,222,249
Cash Receipts from Other Income		(1,487,818)	11,964,064
Cash Paid to Suppliers		(2,150,918,695)	(1,604,567,549)
Bank & Lease Interest Paid		(359,176,452)	-
Cash paid to Employees and Others		(757,772,491)	(556,383,157)
Cash paid to Operational Expenses		(624,114,055)	(610,936,229)
Advance Income Tax Paid		(80,352,592)	(65,165,766)
Cash Flows from Investing Activities:		(83,368,544)	(428,830,158)
Property, Plant and Equipment		(109,674,028)	(441,374,221)
Realized Gain/(loss) from Sale of Marketable Securities		(10,457,145)	823,584
Cash received from Dividend Income		901,146	744,262
Cash Received/(Paid) from Investment in Marketable Securities		35,861,483	10,976,217
Cash Flows from Financing Activities:		(244,995,688)	210,040,204
Increase/ (Decrease) in Lease Liabilities		(11,680,289)	(27,114,885)
Increase/ (Decrease) in Long Term Loan		31,891,767	62,615,532
Increase/ (Decrease) in Short Term Loan		(264,751,652)	345,125,594
Bank & Lease Interest Paid		-	(170,556,546)
Unclaimed dividend Paid		(455,514)	(29,491)
Increase/(Decrease) in cash & cash equivalents		10,901,067	(125,656,341)
Cash and Cash Equivalents at Beginning of year		267,770,086	440,930,216
Effect of exchange rate changes on Cash and Cash Equivalents		3,896,549	86,233
Cash and Cash Equivalents at end of year	11.00	282,567,702	315,360,107
Net operating cash flows per share	31.00	3.16	0.87


Annexed notes are integral part of these financial statements.


 Director Finance & CFO


 Company Secretary


 Acting Managing Director


 Director


 Chairman

Navana Pharmaceuticals PLC.
Notes to the Interim Financial Statements
For the period 01 July 2024 to 31 December 2024

1.0 About the Company

1.01 Legal Form of the Company

Navana Pharmaceuticals PLC was incorporated in Bangladesh on 31 March 1986 vide registration no. C-15428/994 under the Companies Act-1913 (replaced by the Companies Act-1994) as a Private Company Limited by shares. The company was converted into a Public Limited Company on 30 December 2020.

1.02 Address of the Registered Office and Factory

The address of the Company's registered office and Factory located at 1071,1073, North Rupshi, Tarabo, Municipality, Rugganj, Narayanganj. Corporate office address is House 99, Road 4, Block # B, Banani Dhaka-1213, Bangladesh. The Company has several depots around the country.

1.03 Nature of Business Activities

The principal activities of the Company are manufacturing, distribution and marketing of pharmaceutical and veterinary products and sales of the produced items in the domestic and foreign market.

2.00 Basis of Preparation and Presentation of Financial Statements

2.01 Preparation and Presentation of Financial Statements of the Company

These Financial Statements are the unaudited Interim Financial Statements (here after 'the Interim Financial Statements') of Navana Pharmaceuticals Ltd.

These interim financial statements should be read in conjunction with the Financial Statements for the Year ended June 30, 2025 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information. The accounting policies used are consistent with those used in the Annual Financial Statements. These financial statements have been prepared in a condensed form with selected notes following IAS 34: Interim Financial Reporting. The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

2.02 Statement of Compliance

The Financial Statements have been prepared in compliance with the requirements of the Companies Act, 1994 and other relevant local laws as applicable and in accordance with the applicable International Accounting Standards (IASs), The Securities and Exchange Rules, 2020 and International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) and others laws and regulations applicable for the company.

2.03 Regulatory Compliances

As required by the Company, the management complies with the following major legal provisions in addition to the Companies Act 1994 and other applicable laws and regulations:

- a) The Income Tax ACT 2023
- b) Income Tax Rules 2023
- c) The Value Added Tax and Supplementary Duty Act 2012;
- d) The Value Added Tax and Supplementary Duty Rules 2016;
- e) The Customs Act, 1969 and Customs Act 2023
- f) Bangladesh Labour Law, 2006 (Amended 2018);
- g) Negotiable Instrument Act, 1881; and
- h) The Securities and Exchange Rules, 2020.

2.04 Basis of Measurement

The Financial Statements have been prepared on a going concern basis under the historical cost convention applying accrual basis of accounting in accordance with the International Financial Reporting Standards (IFRS's).

The financial statements have been prepared on historical cost convention following the accrual concept of accounting, except for Property, plant & equipment which has been presented under the revaluation model. Investment in shares is valued at par value and cash flow statement has been prepared on cash basis.

2.05 Reporting Period and Comparative Information

The Financial Statements cover 06 months period starting from July 01, 2024 to December 31, 2024

Certain comparative amounts have been re-classified & rearranged to conform to the current period's presentation and all numerical information in the current financial statements as below:

- Statements of Financial Position as of the end of the preceding financial period;
- Statements of Comprehensive Income for the comparable of the preceding financial period;
- Statements of Changes in Equity for the comparable of the preceding financial period;
- Statement of Cash Flows for the comparable of the preceding financial period;

Narrative and descriptive information for comparative information has also been disclosed as required by IASs & IFRSs whenever it is relevant for the understanding of the current Period financial statements.

2.06 Rearrangement of Financial Statement:

The previous period's figure has been rearrangement whenever considered necessary to ensure comparability with the current period presentation as per IAS 8 "Accounting Policies, Changes in Accounting Estimates and Errors".

2.07 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the company's functional currency. All financial information presented has been rounded off to the nearest Taka except where indicated otherwise.

2.08 Property, Plant and Equipment (PPE)

Recognition and Measurement:

Items of property, plant & equipment are measured at cost or revalued amount less accumulated depreciation and impairment losses, if any in accordance with IAS 16: Property, Plant and Equipment. Cost includes expenditure that are directly attributable to the acquisition of the assets. The company has adopted 'Revaluation Model' for stating property, plant & equipment.

Maintenance Activities

The company incurs maintenance costs for all its major items of property, plant and equipment. Repair and maintenance costs are charged as expenses when incurred.

Subsequent Costs

The cost of replacing a part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that future economic benefits associated with the item will flow to the entity and the cost of the item can be measured reliably. All other repair and maintenances costs are charged to the Statement of Profit or Loss and Other Comprehensive Income during the financial period in which they incurred.

Retirements and Disposals

On disposal of fixed assets, the cost and accumulated depreciation are eliminated and gain or loss on such disposal is reflected in the statement of Profit or Loss and Other Comprehensive Income, which is determined with reference to the net book value of the assets and net sales proceeds.

Depreciation

Depreciation is provided to amortize the cost of the assets after commissioning, over the period of their expected useful lives, in accordance with the provisions of IAS 16: Property, Plant and Equipment.

Depreciation on Property, Plant and Equipment has been compute during the periods using reducing balance method except Land & Land Development. Depreciation has been charged on addition when the related PPE are available.

After considering the useful life of assets as per IAS 16, the annual depreciation rates have been applied as under which is considered reasonable by the management.

Rate of Depreciation:

Particulars	Rate	Particulars	Rate
Land and Land Development		Vehicles	
Land and Land Development	Nil	Transport & Vehicles	20%
Building & Other Construction		Motor Cycle	20%
Factory Building	10%	Furniture & Fixture	
Office Decoration	10%	Furniture & Fixtures	10%
Pump House Construction	20%	Rack & Pallets	15%